Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
|
Lenacapavir is already approved for treatment of HIV,
and is under regulatory review for prevention, but it has a price tag of
$42,250. As a result, ... |
ANAC Series Addresses HIV Risk and Barriers in Transgender Health Care
“ HIV testing as a whole in the United States will be severely—and I mean severely with all capital letters—cut, and the people that will suffer the ... View article...